Low-dose naltrexone for treatment of dermatologic conditions: A clinical review
Journal of the American Academy of Dermatology · 2025-09
DOI: 10.1016/j.jaad.2025.09.028 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of the American Academy of Dermatology, 2025-09. Verfasst von Maggie H Zhou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Columbia University Vagelos College of Physicians and Surgeons, New York, New York. Hauptthemen laut MEDLINE: Naltrexone, Narcotic Antagonists, Skin Diseases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 60 Literaturangaben.
Abstract (Originalsprache)
Naltrexone is a long-acting opioid receptor antagonist that may be compounded at lower doses (1-5 mg) to treat inflammatory or autoimmune conditions. Low-dose naltrexone (LDN) transiently blocks the opioid receptor, resulting in increased ligand and receptor expression, favoring κ over μ receptors and decreasing inflammatory mediators and itch. In addition, LDN antagonizes nonopioid receptors, including the pro-inflammatory toll-like receptor 4. Altogether, the anti-inflammatory properties of LDN have supported its use in dermatologic conditions, including Hailey-Hailey disease, Darier disease, pruritus, lichen planus, psoriasis, dermatomyositis, hidradenitis suppurativa, and body-focused repetition behaviors. LDN has demonstrated efficacy in treating these dermatologic conditions with improvement in disease severity, body surface area involvement, and associated symptoms. However, clinical response may vary based on initial disease presentation. There is also evidence supporting LDN in combination with other anti-inflammatory agents. Fewer side effects have been reported with LDN compared to standard naltrexone doses, though larger studies are required to optimize dosage and management. LDN is commonly compounded by a pharmacy, which may pose barriers to access. In this clinical review, we describe updated and practical uses of LDN in inflammatory dermatologic conditions, associated side effects, cost barriers, and comparisons to standard naltrexone doses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Columbia University Vagelos College of Physicians and Surgeons, New York, New York.
- Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina, Charleston, South Carolina.
- Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida.
- Department of Dermatology, Weill Cornell Medicine, New York, New York. Electronic address: shl9032@med.cornell.edu.
Zitieren
APA
Zhou, M. H., Elston, D. M., Morrison, B. W., & Lipner, S. R. (2025). Low-dose naltrexone for treatment of dermatologic conditions: A clinical review. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2025.09.028
Vancouver
Zhou MH, Elston DM, Morrison BW, Lipner SR. Low-dose naltrexone for treatment of dermatologic conditions: A clinical review. Journal of the American Academy of Dermatology. 2025. doi:10.1016/j.jaad.2025.09.028
BibTeX
@article{Zhou2025,
author = {Zhou, Maggie H and Elston, Dirk M and Morrison, Brian W and Lipner, Shari R},
title = {Low-dose naltrexone for treatment of dermatologic conditions: A clinical review},
journal = {Journal of the American Academy of Dermatology},
year = {2025},
doi = {10.1016/j.jaad.2025.09.028}
}
EUVIMED